Vor Biopharma Inc
$ 13.16
-8.10%
05 Jun - close price
- Market Cap 713,086,000 USD
- Current Price $ 13.16
- High / Low $ 14.45 / 12.90
- Stock P/E N/A
- Book Value -4.24
- EPS -70.40
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.25 %
- 52 Week High 65.80
- 52 Week Low 3.62
About
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$37.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-30 | 2025-11-13 | 2025-08-12 | 2025-05-14 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-07 | 2023-08-10 |
| Reported EPS | -0.726 | 307.53 | -121.6 | -251.24 | -0.26 | -0.44 | -0.4 | -0.41 | -0.45 | -0.39 | -0.49 | -0.45 |
| Estimated EPS | -0.7825 | -1.191 | -0.1 | -0.2243 | -0.208 | -0.3067 | -0.4 | -0.42 | -0.38 | -0.5 | -0.47 | -0.43 |
| Surprise | 0.0565 | 308.721 | -121.5 | -251.0157 | -0.052 | -0.1333 | 0 | 0.01 | -0.07 | 0.11 | -0.02 | -0.02 |
| Surprise Percentage | 7.2204% | 25921.1587% | -121500% | -111910.7% | -25% | -43.4627% | 0% | 2.381% | -18.4211% | 22% | -4.2553% | -4.6512% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VOR
2026-06-02 08:40:42
Vor Bio (Nasdaq: VOR) granted equity awards, including 61,050 stock options and 12,900 Restricted Stock Units (RSUs), to 10 newly hired employees on June 1, 2026. These awards, part of its 2023 Inducement Plan, are designed to attract talent and vest over four years. The market reacted negatively to the news, with Vor Bio's stock declining by 6.25% on the day of publication.
2026-06-01 20:40:28
Vor Bio, a clinical-stage biotechnology company, announced the grant of stock options and restricted stock units (RSUs) to 10 newly hired employees as an inducement to employment. These grants, totaling 61,050 stock options and 12,900 RSUs, were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Both the options and RSUs have a four-year vesting schedule, contingent on continued employment.
2026-05-30 02:09:32
Vor Biopharma's price target has been decreased by 10.34%, bringing it down to $37.13. This adjustment reflects a recent analytical re-evaluation for the company.
2026-05-28 18:39:39
Vor Bio (Nasdaq: VOR) announced it will provide a corporate update in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, from 9:55 a.m. to 10:25 a.m. ET. A live webcast and 30-day replay will be available on the company's investor website. This announcement follows recent clinical and financial updates from the clinical-stage biotechnology company, which focuses on autoimmune disease treatments.
2026-05-28 12:39:01
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company, announced its participation in the 2026 Jefferies Global Healthcare Conference. The company will provide a corporate update during a fireside chat on Wednesday, June 3, 2026, from 9:55 am to 10:25 am ET. A live webcast and replay will be available on Vor Bio's investor relations website for those interested.
2026-05-28 06:40:28
This article provides news updates for VOR BIOPHARMA INC (NASDAQ:VOR), including recent announcements regarding an inducement grant, participation in the 2026 Jefferies Global Healthcare Conference, and the publication of an interim analysis for a Phase 3 trial. It also lists the company's first-quarter 2026 financial results and corporate update. The current stock price and after-hours movements are also provided.
